Johnson & Johnson $JNJ Shares Bought by Harvest Portfolios Group Inc.

Harvest Portfolios Group Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 8.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 373,640 shares of the company’s stock after purchasing an additional 28,938 shares during the period. Johnson & Johnson makes up approximately 1.3% of Harvest Portfolios Group Inc.’s holdings, making the stock its 23rd largest holding. Harvest Portfolios Group Inc.’s holdings in Johnson & Johnson were worth $57,074,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the first quarter valued at about $48,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $52,000. Finally, Pandora Wealth Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $65,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $186.92 on Friday. The company has a market capitalization of $450.33 billion, a P/E ratio of 18.04, a PEG ratio of 2.19 and a beta of 0.38. The company has a 50-day moving average of $184.06 and a 200-day moving average of $168.42. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JNJ shares. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. UBS Group boosted their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Citigroup upped their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.